Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Morlacchi, Piera (2007)
Publisher: Massachusetts Institute of Technology Press (MIT Press)
Languages: English
Types: Article
When Victoria Hale first came up with the notion of starting the Institute for OneWorld Health (iOWH), some cautioned that the idea of a non-profit pharmaceutical company developing drugs to treat neglected diseases was a proven loser. The more direct among them might also have inquired why a successful scientist, trained in being analytic, consistent and logical, would undertake such an evidently hopeless project. Yet a few years later, iOWH has not only achieved its first drug approval (i.e. Paramomycin for the treatment of leishmaniasis or ‘black fever’, approved for use in India), it has also seen that same drug included in WHO’s Essential Medicines list, and has research results in the New England Journal of Medicine. This turnaround raises a question: Did skeptics fail to grasp Hale’s clever insights, misjudge the depth of her commitment, or underestimate the extent of her potential good fortune? Put more simply, is Hale’s a story of smarts, guts, and luck?
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Augier, M. and K. Kreiner (2000). “An Interview with James G. March.” Journal of Management Inquiry 9(3): 284-287.
    • Check Hayden, E. (2007). “Straight talk from ... Victoria Hale.” Nature Medicine 13(11): 1274.
    • Coutu, D. and J. G. March (2006). “Ideas as Art.” Harvard Business Review: 83-89.
    • Feynman, R. (1999). The Pleasure of Finding Things Out. London, Penguin books.
    • Hale, V. (2008). “Seeking a Cure for Inequity in Access to Medicines.” Innovations 2(4): 105-117.
    • Kapczynski, A., S. Chaifetz, et al. (2005). “Addressing Global Health Inequities: An Open Licensing Approach for University Innovations.” Berkeley Technology Law Journal 20: 1031- 1114.
    • Love, J. P. and T. Hubbard (2004). Make Drugs Affordable: Replace TRIPS-Plus with R&D Plus. 2007.
    • March, J. G. (1971). The Technology of Foolishness. Decisions and Organizations. J. G. March. New York, Blackwell.
    • March, J. G. (1978). “Bounded Rationality, Ambiguity, and the Engineering of Choice.” The Bell Journal of Economics 9(2): 587-608.
    • Maurer, S. M., A. Rai, et al. (2004). “Finding Cures for Tropical Diseases: Is Open Source an Answer?” PLOS Medicine 1(3): 183-186.
    • Morlacchi, P. (2006). “Simple Technologies that Save the World: The Auto-disable Syringe and the Movement for Safe Injection.” Unpublished manuscript.
    • Sarasvathy, S. D. (2001). “Causation and Effectuation: Toward a Theoretical Shift from Economic Inevitability to Entrepreneurial Contingency.” Academy of Management Review 26(2): 243-263.
    • Sarasvathy, S. D. and N. Dew (2005). “Entrepreneurial Logics for a Technology of Foolishness.” Scandinavian Journal of Management 21(4): 385-406.
    • Tansey, G. (2006). Expanding Policy Options for Access to Medicines for All. Negotiating Health. Intellectual Property and Access to Medicines. P. G. T. a. D. V.-E. Roffe. London, Earthscan.
    • Trouiller, P., P. Olliaro, et al. (2002). “Drug Development for Neglected Diseases: A Deficient Market and a Public Health Policy Failure.” Lancet 359(9324): 2188-2194.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article